MARKET

CELC

CELC

Celcuity Inc
NASDAQ
99.16
+0.11
+0.11%
After Hours: 99.45 +0.29 +0.29% 19:17 12/18 EST
OPEN
99.05
PREV CLOSE
99.05
HIGH
101.67
LOW
97.27
VOLUME
779.77K
TURNOVER
--
52 WEEK HIGH
112.64
52 WEEK LOW
7.58
MARKET CAP
4.59B
P/E (TTM)
-27.0117
1D
5D
1M
3M
1Y
5Y
1D
CELCUITY INC <CELC.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $118 FROM $97
Reuters · 1d ago
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
NASDAQ · 2d ago
Weekly Report: what happened at CELC last week (1208-1212)?
Weekly Report · 4d ago
RH Posts Strong Q3 Sales, Joins Canopy Growth, Tilray Brands, Frequency Electronics And Other Big Stocks Moving Higher On Friday
Benzinga · 6d ago
Celcuity Price Target Announced at $126.00/Share by Wells Fargo
Dow Jones · 6d ago
Wells Fargo Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $126
Benzinga · 6d ago
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Joint (JYNT)
TipRanks · 6d ago
Wells Fargo bullish on Celcuity, initiates with an Overweight
TipRanks · 6d ago
More
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

Webull offers Celcuity Inc stock information, including NASDAQ: CELC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELC stock methods without spending real money on the virtual paper trading platform.